Plasma proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) and the risk of chronic kidney disease progression in patients with type 2 diabetes
Main finding · Composite renal outcomeResult — go to the resultAdjusted fold risk 1.47 95% CI 1.02–2.12Authors' conclusion
A high level of plasma PCSK9 is independently associated with an increased risk of CKD progression, suggesting the need to further elucidate the role of PCSK9 in diabetic kidney disease. Future studies are warranted to explore whether PCSK9 is a potential target for prevention and treatment of kidney disease.
Study context
- Population
- Outpatients with T2D from a regional hospital and a primary care facility226 renal events
- Participants
- 1,902 outpatients
- Exposure
- Plasma PCSK9
- Outcome
- Chronic kidney disease (CKD) progression: composite of incident ESKD (sustained eGFR < 15 mL/min/1.73 m², maintenance dialysis or renal death) or doubling of serum creatinine
- Follow-up
- Median 7.2 years
Main finding
Composite renal outcome · median 7.2 years
Adjusted fold risk
1.47
95% CI 1.02–2.12
As reported in the abstract
- Per 1 SD increment of plasma PCSK9, fold increased risk (95% CI 1.10-1.48), adjusted for known cardio-renal risk factors
- 1.27
Observational data: associations, not effects.
Further findings
End stage kidney disease (ESKD) as outcome; non-renal death as competing risk
- Consistent data were obtained
Original publication
Plasma proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) and the risk of chronic kidney disease progression in patients with type 2 diabetes. Diabetes Obes Metab. Published 29 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →